Why the study?
Amyloid-induced cardiomyopathy has distinct characteristics compared to non-amyloid cardiomyopathies, requiring specific management strategies.
This review outlines the cardiovascular manifestations and specific management strategies for cardiac amyloidosis, emphasizing the importance of multidisciplinary care.
Supports multidisciplinary care in cardiac amyloidosis; leaves open optimal strategies pending prospective validation.
Cardiac amyloidosis, the majority of cases of which are due to immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR), affects different aspects of the heart and cardiovascular system. Amyloid-induced cardiomyopathy, clinically manifesting with heart failure and electrophysiological abnormalities, has distinct characteristics compared to non-amyloid cardiomyopathies. Accordingly, specific management strategies are required. This paper will review the cardiovascular manifestations of patients with cardiac amyloidosis and their suggested treatment strategies, emphasizing the importance of multidisciplinary care.
No takes yet. Share an insight, caveat, or question.
Zadok et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: